Raymond Little, MD
Cardiovascular Disease · Humble, TXNPI 1669485546
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (49.3%), education and food and beverage — rather than concentrated in one kind of arrangement. Angiodynamics, Inc. accounts for 90.4% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2022 at $16,473 and has fallen 98.3% since, to $276 in 2025. Among cardiovascular disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 63 payments — averaging $484.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$28K
- Medtronic$1K
- Philips North America LLC$407
- Abbott$161
- Tactile Systems Technology Inc$152
- Recor Medical Inc$147
- plus $693 from 14 others
Across 192 payments — averaging $2159.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bayer$115K
- Amgen$81K
- Astrazeneca UK Limited$71K
- AstraZeneca$71K
- American Regent$42K
- Novartis$15K
- plus $20K from 2 others
What the payments were for
- Travel & lodging$1,1524%
- Food & beverage$2,3208%
- Education$12,00039%
- Other$15,03749%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 9 | $27,586 |
| Medtronic | 10 | $1,363 |
| Philips North America LLC | 7 | $407 |
| Abbott | 3 | $161 |
| Tactile Systems Technology Inc | 7 | $152 |
| Recor Medical Inc | 1 | $147 |
| Cook Medical LLC | 2 | $129 |
| Novartis | 4 | $126 |
| Boston Scientific | 5 | $123 |
| Boehringer Ingelheim | 3 | $53 |
| Cardinal Health 200 LLC | 1 | $49 |
| Amgen | 2 | $39 |
| Smith+Nephew | 1 | $26 |
| Catheter Precision, Inc. FKA Ra Medical Systems, Inc. | 2 | $26 |
| Paratek Pharmaceuticals, Inc. | 1 | $25 |
| Cordis US CORP. | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Novo Nordisk | 1 | $21 |
| Pfizer | 1 | $19 |
| Abiomed | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$30,510 in reported general payments places this provider in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 22 | $22,108 |
| XareltoRivaroxaban | 13 | $14,301 |
| Hydralazine Hcl | 66 | $1,190 |
| Labetalol Hcl | 16 | $1,038 |
| ClopidogrelClopidogrel Bisulfate | 69 | $940 |
| Rosuvastatin Calcium | 52 | $692 |
| Losartan Potassium | 63 | $619 |
| Lisinopril | 61 | $595 |
| Verapamil ErVerapamil Hcl | 18 | $531 |
| Ezetimibe | 20 | $529 |
| Nifedipine ErNifedipine | 13 | $528 |
| Atorvastatin Calcium | 55 | $505 |
| Potassium Chloride | 20 | $361 |
| Metoprolol Succinate | 44 | $350 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 31 | $278 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $19 | $22,10822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,515 cardiovascular disease providers in Texas.
Other cardiovascular disease in Humble
- Naddi MarahHumble$133K
- Ramin Farzaneh-FarDallas$17.1M
- John OsborneGrapevine$1.3M
- Darren McGuireDallas$1.2M
- Peter McCulloughDallas$664K
- Ann NavarDallas$616K
- Biykem BozkurtHouston$606K
- Milton PackerDallas$530K
- Amarinder BindraDallas$512K
- Robert SalazarKingwood$478K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.